The Latest

RegenMed is proud to announce that Dr. Marcus Klingenberg will be acting as a Principal Investigator for four separate Physicians-Owned Circles in the field of micronized adipose tissue therapies for musculoskeletal indications. Dr. Klingenberg is an internationally recognized orthopedic surgeon; patients from throughout Europe travel to the BetaKlinik which he co-founded in 2008 in Bonn, Germany. The four separate Observational Protocols will cover MFAT treatment for unilateral knee cases, bilateral knee cases, unilateral hip cases, and bilateral hip cases. They will generate statistically and clinically significant longitudinal datasets, including specific devices utilized, within only a few months. Those proprietary data sets, and resulting license fees, will be owned 85% by participating POC members. RegenMed is already in preliminary discussions for pre-licensing arrangements with MFAT device manufacturers.Dr. Klingenberg’s Observational Protocols will be published shortly on RegenMed’s POC Library Page. Qualifying clinicians interested in joining one more of those POC’s are encouraged to apply.

In the rapidly evolving landscape of healthcare, data has become the new currency. Physicians, as the frontline caregivers, hold a unique position to leverage this data for better patient outcomes and streamlined practices. But why is it crucial for physicians to own their patient data? 1. Enhanced Patient Care: Owning patient data allows physicians to have a comprehensive view of a patient's health history, enabling more accurate diagnoses and personalized treatment plans. 2. Improved Efficiency: With direct access to patient data, physicians can reduce administrative burdens, streamline workflows, and focus more on what matters most—patient care. 3. Data Security and Privacy: By owning the data, physicians can ensure it is stored securely and complies with privacy regulations, building trust with patients. 4. Innovation and Research: Access to robust data sets can fuel medical research and innovation, driving advancements in healthcare technologies and treatments. 5. Empowered Decision Making: Physicians can make data-driven decisions, leading to better outcomes and a more proactive approach to healthcare. At RegenMed, we believe in the power of data ownership. Our platform - Circles - empowers physicians to take control of their patient data, providing the tools and support needed to navigate the complexities of data management. Join Circles today and experience the future of healthcare data ownership:

Executive SummaryFertility medicine is at the forefront of clinical innovation, offering patients an expanding array of treatment options. Yet many clinics struggle to measure outcomes, track long-term success, or collaborate with peers in real-time. RegenMed Circles changes that by giving fertility physicians the tools to collect structured, standardized, and compliant real-world data (RWD) from everyday clinical care. The result? Better insights, improved protocols, and enhanced outcomes — for every patient.While revenue potential through data licensing is a key feature, the primary mission of RegenMed Circles is to create physician-led communities focused on accelerating treatment advancement and clinical excellence. Through Circle participation, clinicians improve patient care while gaining access to rich benchmarking tools, peer collaboration, and professional growth opportunities.IntroductionThe fertility landscape is rapidly evolving. From IVF and IUI to cryopreservation and emerging regenerative therapies like PRP, clinics are offering more options than ever before. But despite technological and clinical advancements, most practices lack the infrastructure to collect meaningful, comparative outcome data across these treatments.This limits a clinic’s ability to improve protocols, benchmark against peers, or contribute to broader research. RegenMed Circles was built to close this gap — giving fertility providers a seamless way to track and analyze outcomes at scale.The Opportunity: Closing the Outcomes GapFertility care is outcome-driven, but few clinics have access to real-time, structured insights about their own performance — let alone how it compares to others. Clinics often struggle to:Standardize outcome tracking across providers and protocolsAnalyze trends over time or across treatment typesShare knowledge or collaborate on clinical advancementsAs patients become more outcome-aware and payers demand more data, the need for structured, real-world evidence is becoming essential — not optional.We can build your Circle based on your preference of outcomes measurements through the creation of Scoring Formulas, like the ones pictured below, to help you identify treatment outcome trends.Regenmed Circles: A Platform for Collaborative CareRegenMed Circles are secure, collaborative networks that enable clinics to:Collect and structure real-world treatment outcomes with zero workflow disruptionCompare anonymized results with national benchmarksCollaborate with peers on protocols, research, and publicationsKeep full ownership and control of their patient dataEach Circle focuses on a specific treatment domain or outcome type, examples include:IVF cycle success and implantation ratesIUI outcomes and ovulation induction effectivenessEgg and embryo freezing protocolsPRP for ovarian and endometrial supportMale fertility treatment response and trendsPhysicians can join existing Circles or propose new ones based on their areas of interest.Real-world evidence is becoming essential — not optional.Improving Patient Outcomes Through Real-World EvidenceBy collecting outcomes data in a structured, longitudinal format, clinics gain powerful tools to improve care:Identify top-performing protocols and refine treatment plansEnhance cycle prep strategies and optimize timingShare de-identified insights across clinical teamsTrack long-term patient success—not just short-term metricsCircle members receive interactive dashboards, cohort-level reports, and access to collaborative datasets. These tools empower fertility providers to continuously improve outcomes — without hiring new staff or disrupting care delivery. See below for some examples of what the platform looks like and how it can be used to assess patient outcomes.Patient PortalInvestigator PortalMonetizing Your Real-World DataIn addition to improving care, RegenMed Circles create sustainable revenue through compliant, de-identified data licensing. Clinics can:License aggregate datasets to pharma, device, or digital health partnersEarn up to 85% of licensing revenueParticipate in studies that shape future treatment developmentRevenue is just the beginning. Circle participation supports scientific publications, conference presentations, and national recognition for clinical leadership.Call to ActionCircles give fertility clinics a powerful way to elevate care and lead innovation. Whether you're optimizing IVF protocols, testing regenerative approaches like PRP, or working to better understand male fertility — Circles make your outcomes work for you.Join a growing network of physician-led innovators who are shaping the future of fertility care with real-world evidence.Visit www.rgnmed.com/circles or contact us to learn how to join or launch your own Circle.Contact UsRegenMed | www.rgnmed.comcircles@rgnmed.com

RegenMed is proud to announce that Ms Laura Prey has joined our corporate board of directors.Ms. Prey brings to the RegenMed board more than three decades of senior-level IT experience in the healthcare, insurance and financial industries. This experience will be invaluable in helping management shape the strategic direction of its patented Circles platforms as the Company serves larger enterprise clients.As a proven visionary leader in Fortune 500 as well as small to mid-size companies, Laura established an enviable track record of accelerating the delivery of innovative technology solutions despite complex business and technical challenges.Laura most recently served as a consultant to the CIO of Optum Florida, helping to drive strategy and agile technology delivery across a wide portfolio of operations and clinical products. Prior to that, she held the position of Vice President, Information Technology at Thrivent, a Fortune 500 Financial Services company where she led technology for life, health and annuity operations.Prior to Thrivent, Ms. Prey oversaw the successful delivery of complex software products for WPS Insurance in connection with the U.S. Department of Defense’s Tricare offering, which serves millions of members of the U.S. military and their families.Ms. Prey received a Bachelor of Business Administration degree in Management Information Systems and an MBA from the University of Wisconsin Madison.

Data: The World’s Most Precious Commodity In the 21st Century, data is the raw material upon which all value-added transactions depend. Manufacturing, , finance, transportation, energy and countless other industries all heavily rely on data to innovate, compete and indeed survive. This is nowhere more true than in healthcare. The $60 billion healthcare data market is growing at over 11% per year. The largest consumer of data will be AI, if it is not already. Indeed, AI is fast running out of training data. This puts a premium on private sources of relevant and high quality data. As with all raw material, clear proof of data ownership is critical. Who Owns That Data? Failure to establish data ownership invites litigation, and the inability to successfully monetize or otherwise use it. For example, in December 2023 the New York Times sued OpenAI and Microsoft for copyright infringement, seeking billions of dollars in damages. This month, Thomson Reuters won a landmark AI copyright infringement case. The federal court held that the defendant used content from Thomson Reuters to develop a competing AI-driven legal research tool. The judge ruled that the defendant’s actions did not qualify as "fair use" under U.S. copyright law. This landmark decision underscores the legal protections surrounding the use of copyrighted materials in AI training and development. This Is Yet One More Challenge For “Big Data” And Healthcare AI Models AI in medicine is already here, and will only become more pervasive. However, the data on which AI healthcare models train is typically of poor quality. Problems include incompleteness, inability to audit original sources, no or irrelevant clinical context, data “cleaning” and other unknown manipulations, irreconcilable data conflicts, no correlated outcomes measures, and stale or undated information. Most of today’s $60 bn. data market represents the exchange and repackaging of such “big data”. AI error rates and “hallucinations” are thus not only inevitable in most AI healthcare solutions, they are dangerous in specific applications such as clinical decision-making. But now there is a deeper problem – who owns the various bits and pieces of data making up a “big data” dataset? EMR companies, medical society registries, hospital systems, researchers, payers, AI start-ups are among the many entities who may have contributed and will claim ownership. The weaknesses of “big data” structures, coupled with competing ownership claims, will make it an increasingly unattractive choice for healthcare data consumers, including AI models. The Circles Solution RegenMed’s Circle datasets are generated and maintained in a closed system which maintains their coherence, transparency, and auditability. They are high-quality – both statistically and clinically significant – with clear ownership and monetization rights vested in the dataset creators. Real world data is likely to become one of the most critical categories of all healthcare data. It will be key to supporting value based medicine, lower costs, faster lab-to-bedside clinical translation, and health equity. RegenMed is well positioned to capture a significant portion of this market.